376 results about "Smoking cessation" patented technology

An electronic cigarette includes a memory, a processor communicatively coupled to the memory and configured to run an electronic cigarette application stored in the memory, and an output circuit that transfers information from the electronic cigarette application to a remote electronic cigarette application separate from the electronic cigarette. An indicator such as an audible indicator and / or a visual indicator provides information, such as an indication that the electronic cigarette needs recharging or an indication to a user implementing a smoking cessation program. The remote electronic cigarette application can be a remote server-based application, a remote cloud-based application, and / or a mobile-device-based application. The remote electronic cigarette application shares transferred information with a social media account. An input circuit receives from the remote electronic cigarette application remote information and / or remote commands.

An automated identification, weight measurement and data reporting system that allows users to have their weight measured at a remote location and sent electronically to a data center. The invention can use biometric identification technology to confirm the identity of the user at the time of the measurement of the user's weight. The user's body weight may be measured via an electronic scale connected to the biometric identification device. The measurement data is then sent via a network (such as the Internet) to a central database. This secure weight measurement data is then used to offer incentives to individuals to lose weight. The more weight an individual loses, the larger the earned incentives. The invention also includes programs to measure health functions and to provide incentives to improve their health including body fat reduction, quitting smoking, reducing their blood pressure, or other health function.

A multi-source electronic vapor cigarette which overcomes the shortcomings of current devices. The device allows a user, when using the device for smoking cessation, to select different levels of nicotine at different times of the day to satisfy different levels of craving. The device holds multiple individual containers of a different liquid concentration of nicotine, flavored or not, or flavored medium only, within one device. A user can select a desired refillable container by operation of a switch to create a vapor passage from the desired container to the mouthpiece. For flavored vapor users, operation of the switch will select a container holding the desired flavor. The user can take a puff of one flavor vapor followed by another without mixing flavors within the device. The device allows any desired combination by inserting individual containers the user fills with their choice of liquid.

A multi-flavor electronic vapor device which overcomes the shortcomings of current devices. The device allows a user, when using the device for smoking cessation, to select different levels of nicotine at different times of the day, to satisfy different levels of craving. The device holds multiple individual containers of a different liquid concentration of nicotine, flavored or not, or flavored medium only, within one device. A user can select a desired refillable container by turning the cap assembly containing the mouthpiece nozzle to the position of the desired container. For flavored vapor user, turning the cap will select a containers holding the desired flavor. The user can take a puff of one flavor vapor followed by another without mixing flavors within the device. The device allows any desired combination by inserting individual containers the user fills with their choice of liquid.

The invention relates to a traditional Chinese medicine electronic cigarette for quitting smoking, which can effectively solve the problems that an existing smoking-quitting product still contains nicotine and is difficult to play a fast smoking-quitting role. The health care type traditional Chinese medicine electronic cigarette for quitting smoking comprises a battery pole, an atomizer and a smoking-quitting medicament mouth, wherein the front end of the atomizer is placed in the smoking-quitting medicament mouth, the back end of the atomizer is connected with the battery pole, the smoking-quitting medicament mouth comprises a hollow columnar body, a vent hole arranged at the center of the front end and a medicament cabin in the hollow columnar body, and air-permeable cotton and a medicament are filled in the medicament cabin; the atomizer is characterized in that an electrode is arranged at the center of a connecting body, an insulating silicon tube is sheathed on the electrode, a heating element which is wounded on a wick is arranged at the upper end part of the tube, two ends of the wick are installed on the connecting body, and mixed solution of electronic cigarette oil and smoking-quitting medicament liquid is absorbed on the wick; and the battery pole is characterized in that a battery is arranged in an internal cavity, a CPU (central processing unit) control board is arranged at the back end of the cavity, the front end of the battery pole is arranged on the connecting body, the cavity of the battery pole between the connecting body and the battery constitutes an air chamber, and an air inlet hole is arranged on the battery pole. The health care type traditional Chinese medicine electronic cigarette for quitting smoking has significant smoking-quitting effect and has no adverse effects.

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

Addiction treatment, specifically smoking cessation, can be effectively treated utilizing stimulation of low resistance skin locations by employing a combination of an electrical current and a laser beam. In a preferred stimulation treatment, pulsed stimulation is used, stimulating skin locations in the ear and nose areas. The present stimulation treatment is simple and cost effective, lasting about 10-20 minutes per treatment session, with an average of 1 to 2 repeated treatment sessions per person. The present stimulation treatment is proven to be effective in assisting in smoking cessation, showing high percentage of long term smoking abstinence in just one treatment session.

Systems and methods for monitoring of biometric and contextual variables to assist in screening for, quantification of, and prediction of smoking behavior, and for assisting in smoking cessation are described.

Dosage forms of a nicotine delivery system are disclosed in which a mucoadhesive film, made up of one or more non-microbial hydrocolloid(s) and an effective dose of nicotine, dissolves when applied intraorally to release the nicotine which is absorbed through the oramucosac and directly reaches systemic circulation. Methods for preparing various versions of the dosage forms are disclosed. Methods to assist smoking cessation or provide substitutes for smoking by administrating the dosage form are also provided.

Devices, methods and systems are disclosed for assisting patients in behavioral modification and cessation programs aimed at terminating undesired behaviors such as smoking, alcohol use and others. Patient devices configured to be easily carried or worn including test units such as carbon monoxide blood level sensors with automated patient prompting for self-testing, analysis of test results and data logging are included in a networked system with a specifically designed treatment modality. Devices and methods disclosed are particularly suited to use in smoking cessation treatment and programs.

Methods of use of a nasal insert to support smoking cessation, and methods of use of a nasal insert to reduce or eliminate snoring, and a method of use of a nasal insert to reduce the severity or to eliminate obstructive sleep apnea, and a method of use of a nasal insert to gain smoother, easier breathing through the nose. The nasal insert comprises a body having an inner surface which defines an air passageway surrounded by an outer surface of soft, flexible material. The nasal insert body can have a first portion and a second portion where the outer surface of said nasal insert body is configured to the nasal cavity.

The object of the present invention is to provide a system and method to enable a person wishing to quit smoking to carry with him a smoking cessation device that will assist the user in behavior modification, and in particular curbing and dealing with nicotine cravings. The current invention makes use of widely available and familiar infrastructure of hand held devices such as cellular phones and cellular networks. Other mobile devices having digital displays may also be used such as mobile touchscreens (i.e. Ipad, Kindle, etc.) digital music players such as the iPod and other similar devices. Smoking cessation and craving reduction are achieved through coordinated messaging reinforcement coupled with craving reduction training including controlled deep breathing exercises prompted by the device.

The invention provides an edible cigarette and a preparation method thereof. The edible cigarette comprises edible cigarette functional composition and carrier composition, wherein the edible cigarette functional composition comprises 0.01-2 weight percent of physiological strength substance, 0.01 percent-5 percent of aromatic essential oil, ethanol solution with 0.01-5 weight percent of tobacco aroma substance, 0.01-16 weight percent of Chinese herbal medicine composition and 0.01 percent-1.2 percent of taste agent; the physiological strength substance is tobacco alkaloid, tea alkaloid and one or more of salt, glycosides, esters and amides of the tobacco alkaloid and the tea alkaloid; and the Chinese herbal medicine composition is extract or broken matter of Chinese herbal medicine. The technical scheme of the invention solves the problems in the prior art that the aroma of the aromatic essential oil and that of the tobacco aroma cannot be effectively blended, and the edible cigarette products containing the substances have poor storage stability, and the invention provides the edible cigarette product which does not contain the harmful compositions of tobacco and also has the health care function, the aroma therapy function and the substitutive therapy function for smoking cessation.

A cessation and management method comprising removing a physical aspect, wherein removing the physical aspect includes instructing a user to manipulate a delivery time of a substance, and instructing the user to control a consumption amount of the substance, correcting a behavioral association, wherein correcting the behavioral associations includes instructing the user to determine a personal goal and fixing it to a medium, facilitating the user to reprogram thoughts and activities, and facilitating the user to replace an old negative behavior with a new positive behavior, and providing a plurality of life cards to assist the removal of the physical aspect and the correction of the behavioral associations. Furthermore, an associated smoking cessation kit and weight management kit is also provided.

Systems and methods for monitoring of biometric and contextual variables to assist in screening for, quantification of, and prediction of smoking behavior, and for assisting in smoking cessation are described.

A method for encouraging behavior change consisting of three phases of steps: an extended preparation phase, a behavior change phase, and a maintenance / relapse prevention phase that may be used to supplement traditional human behavior modification programs, thereby improving their outcomes. The extended preparation phase is designed to help an individual develop the essential skill of keeping his / her word consistently. To accomplish this goal, physical exercise is preferably used as a training ground to help an individual recognize and overcome any psychological and emotional barriers to keeping his / her word. Once word-keeping mastery has been achieved in the physical exercise context, an individual transfers this skill to active behavior change, such as weight loss, smoking cessation, gambling avoidance, etc. Once targeted goals are reached, a long-term maintenance / relapse prevention phase begins. During all three phases, physical exercise is used in a novel manner to strengthen and reinforce daily word-keeping mastery.

Smoking cessation lighter is configured for lighting cigarettes for a smoker, and learning software is provided for monitoring smoking behavior of a smoker during a first data collection period and guiding a smoker's smoking cessation by directing the smoker when the smoker is to smoke a cigarette based on data collected during the first data collection period. The learning software monitors user behavior and collects data during use of the lighter by the smoker after the initial data collection period in order to analyze and further guide the smoker based on the smoker's cheating behavior, the smoker's behavior of lighting a cigarette for a friend, and the smoker's behavior of skipping use of the lighter at a time when the smoker has been directed to light a cigarette by the lighter.

Disclosed is a method of promoting smoking cessation in a human comprising administration to the human an effective amount of reboxetine in combination with the administration of a smoking-cessation enhancing agent. Also disclosed is a composition for administration to a human for promoting smoking cessation comprising reboxetine and smoking-cessation enhancing agent. Examples of the smoking-cessation enhancing agents include nicotine, an antidepressant, a nicotine receptor antagonist, and an opioid antagonist.

An electronic cigarette is equipped with a memory and ability to record the amount and duration of inhalation of nicotine vapor. The electronic cigarette may be integrated with a smart phone application or other software to record usage and provide feedback to the smoker. The application may include an algorithm for the development of a withdrawal schedule for the user to quit smoking or vaping.

The invention relates to an electronic cigarette smoking data acquisition system. The electronic cigarette smoking data acquisition system comprises an electronic cigarette, a mobile terminal and a data processing server, wherein the electronic cigarette is communicated with the mobile terminal in a wireless way, data information of the electronic cigarette is shared by the mobile terminal, the information such as smoking time, smoking position and smoking frequency is acquired by the mobile terminal and is stored in the data processing server. The smoking statistics data is acquired and outputted to the mobile terminal through a wireless module, so that a smoking statistics signal such as a smoking time signal, a smoking frequency signal and a smoking quantity signal can be known by people in time, and the smoking cessation activity can be carried out according to the smoking statistics signal. The electronic cigarette smoking data acquisition system has advantages that the application function is rich, the expandability is good, and the like.

A process for manufacturing a tobacco leaf substitute that maintains the taste and flavor similar to typical commercial cigarettes utilizing: (1) the leaves of Morus alba L, 1354MI, (2) leaves of Lillium longiflorum; (3) and leaves of herbs, is comprised of, including but not limited to: 1) a salted water soaking; 2) washing; 3) 1st drying; 4) steaming; and 5) 2nd drying. The tobacco leaf substitute of this invention emits a minute amount of nicotine than conventional cigarettes. The tobacco leaf substitute has a beneficial effect of being free of any cigarette-related poisons stemming from traces of mercury, nickel, and cadmium found in typical commercially available cigarettes. The cigarette substitute of this invention helps to quit smoking and eliminates poisons from the bloodstream of pre-smokers.

The invention relates to an electronic smoking set and a smoking frequency detection method for the electronic smoking set. The electronic smoking set comprises a smoking set body, a temperature sensing element and a circuit board, after energization, heat is produced inside the smoking set body, and the heat heats the air inside the smoking set body. A temperature sensing end of the temperature sensing element is located in an airflow channel, so that the heat produced inside the smoking set body can radiate to the temperature sensing end of the temperature sensing element. When a smoking action is produced, outside air enters an air inlet channel from an air inlet and flows into a containing cavity, and airflow flowing in the airflow channel is formed, so that temperature values detected by the temperature sensing end during smoking and non smoking situations are different and temperature variation is known; and the circuit board obtains smoking frequency according to the temperature variation, so that the smoking frequency can be obtained only by detecting the temperature variation by virtue of the temperature sensing end of a temperature sensing wire without inducing negative pressure, so that the smoking frequency detection accuracy can be effectively improved.

A kit to alleviate tobacco-smoking withdrawal symptoms in a patient is disclosed which comprises:(a) a therapeutically effective amount of nicotine, at least one active nicotine metabolite, a combination of nicotine and an active nicotine metabolite, or an azapirone, or a pharmaceutically acceptable salt thereof;(b) a transdermal delivery system consisting essentially of a bupropion base in a therapeutically effective amount; and(c) a packaging material surrounding (a) and (b).